VBI Vaccines Announces Results of Annual General Meeting
VBI Vaccines announced the results of its annual general meeting of shareholders held on June 25, 2024. The meeting saw representation by 13,879,327 common shares, accounting for 48.39% of the company's outstanding shares. Shareholders voted on eight director nominees, all of whom were re-elected. The votes were as follows: Steven Gillis (80.58% for, 19.42% withheld), Damian Braga (80.35% for, 19.65% withheld), Joanne Cordeiro (83.07% for, 16.93% withheld), Michel De Wilde (79.77% for, 20.23% withheld), Vaughn Himes (83.88% for, 16.12% withheld), Blaine H. McKee (83.12% for, 16.88% withheld), Jeffrey R. Baxter (81.10% for, 18.90% withheld), and Nell Beattie (81.73% for, 18.27% withheld). Additionally, EisnerAmper LLP was appointed as the independent registered public accounting firm until the next annual meeting. More details can be found in the company's SEC and SEDAR filings.
- None.
- 48.39% shareholder representation indicates less than half of the company's shares were voted.
- Some director nominees received relatively high percentages of withheld votes, such as Michel De Wilde with 20.23%.
The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 13,879,327 Common Shares, representing
The voting results with respect to each of the following eight director nominees, as described in the Company's proxy statement dated April 29, 2024 (the "Proxy Statement"), all of whom previously served as directors of the Company, were as follows:
Nominee |
Votes For |
% |
Votes Withheld |
% |
||||
Steven Gillis |
3,663,424 |
|
882,856 |
|
||||
Damian Braga |
3,651,602 |
|
892,907 |
|
||||
Joanne Cordeiro |
3,776,579 |
|
769,703 |
|
||||
Michel De Wilde |
3,625,156 |
|
919,353 |
|
||||
Vaughn Himes |
3,813,210 |
|
733,071 |
|
||||
Blaine H. McKee |
3,778,849 |
|
767,432 |
|
||||
Jeffrey R. |
3,685,583 |
|
858,927 |
|
||||
Nell Beattie |
3,714,249 |
|
830,260 |
|
The Shareholders also voted in favor of appointing EisnerAmper LLP as VBI's independent registered public accounting firm until the next annual meeting of shareholders and authorizing the audit committee of VBI's board of directors to fix its remuneration.
Additional information regarding the results of all matters voted upon at the Meeting may be found in the Company's SEC and SEDAR filings.
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology and a proprietary mRNA-launched eVLP (“MLE”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in
Website Home: http://www.vbivaccines.com/
News and Resources: http://www.vbivaccines.com/news-and-resources/
Investors: http://www.vbivaccines.com/investors/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625000048/en/
VBI Investor and Media Contact
Amy
Phone: (617) 830-3031 x151
Email: IR@vbivaccines.com
Source: VBI Vaccines Inc.
FAQ
What were the results of VBI Vaccines' 2024 annual general meeting?
Which directors were re-elected at VBI Vaccines' 2024 annual general meeting?
How many shares were represented at VBI Vaccines' 2024 annual general meeting?
What percentage of votes did Steven Gillis receive in favor at VBI Vaccines' 2024 annual general meeting?